CONCLUSION:
In summary, in this real-world difficult asthma cohort, OMA and MEPO
were used for distinct SA phenotypes in which they were both
multidimensionally effective. Among these phenotypes, we identified some
features independently associated with response, which may assist
clinicians. In turn, those findings reiterated the importance of
detailed characterisation and addressing treatable traits alongside
consideration of biologics use in more severe asthma. To further enhance
the personalised and optimal use of biologic therapies, future research
should develop a deeper endotypic understanding of asthma biologic need
and responsiveness.